Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
SUM149PT | Dinaciclib | pan CDK | Cell cycle | 0.013311 | -0.5676 | 0.6891 | 0.3611 | 4.0226 | 0.016068 | 0.99946 |
HCC1806 | Dinaciclib | pan CDK | Cell cycle | 0.013395 | -0.4585 | 0.6439 | 0.3114 | 3.4710 | 0.016174 | 0.99891 |
SUM1315MO2 | Doxorubicin | Chemo | Chemotherapy | 0.018222 | -0.0635 | 0.5132 | 0.1324 | 2.0980 | 0.016338 | 0.96491 |
SUM1315MO2 | Trametinib | MEK | MAPK/nRTK | 0.021115 | 0.1329 | 0.3887 | 0.0532 | 1.0540 | 0.01638 | 0.99458 |
HCC1143 | Dinaciclib | pan CDK | Cell cycle | 0.015148 | -0.2527 | 0.5451 | 0.1106 | 5.0000 | 0.016398 | 0.9989 |
SK-BR-3 | Abemaciclib | CDK4/6 | Cell cycle | 0.035311 | 0.1432 | 0.5363 | 0.0387 | 0.6381 | 0.016543 | 0.96857 |
MDA-MB-361 | Palbociclib | CDK4/6 | Cell cycle | 0.019625 | 0.1481 | 0.4822 | 0.0065 | 2.1670 | 0.01672 | 0.99444 |
CAL-51 | Dinaciclib | pan CDK | Cell cycle | 0.014709 | -0.3585 | 0.5985 | 0.2374 | 3.5319 | 0.017105 | 0.99939 |
MDA-MB-361 | Topotecan | Topo I | Chemotherapy | 0.011361 | -0.7622 | 1.1276 | 0.2239 | 1.9673 | 0.01715 | 0.98983 |
MDA-MB-361 | Doxorubicin | Chemo | Chemotherapy | 0.012289 | -0.7224 | 0.9125 | 0.1900 | 2.1676 | 0.017167 | 0.96442 |
SUM159PT | Dinaciclib | pan CDK | Cell cycle | 0.016967 | -0.0646 | 0.4536 | 0.1030 | 5.0000 | 0.017277 | 0.99948 |
HME1 | Volasertib | PLK | Cell cycle | 0.017242 | -0.0817 | 0.4263 | 0.1273 | 3.6204 | 0.017483 | 0.99425 |
MCF 10A | Dinaciclib | pan CDK | Cell cycle | 0.016244 | -0.2300 | 0.5279 | 0.2344 | 5.0000 | 0.017523 | 0.99904 |
MCF 10A | INK-128 | mTORC1/2 | PI3K/mTOR | 0.024199 | 0.1716 | 0.4673 | -0.0027 | 1.3149 | 0.017581 | 0.99992 |
HCC38 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.01911 | -0.0087 | 0.5361 | 0.0402 | 1.3664 | 0.018127 | 0.99621 |
HCC1419 | Volasertib | PLK | Cell cycle | 0.020718 | 0.0685 | 0.3636 | 0.0462 | 1.8241 | 0.018178 | 0.98538 |
HCC1954 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0096629 | -0.3280 | 0.5536 | 0.1704 | 0.7380 | 0.018218 | 0.98125 |
HCC1428 | Volasertib | PLK | Cell cycle | 0.018634 | -0.0388 | 0.4063 | 0.0917 | 2.1456 | 0.018507 | 0.99276 |
MDA-MB-468 | Dinaciclib | pan CDK | Cell cycle | 0.015576 | -0.4131 | 0.5681 | 0.1843 | 2.8840 | 0.018635 | 0.99641 |
HCC1500 | Dinaciclib | pan CDK | Cell cycle | 0.013792 | -0.5720 | 0.6616 | 0.1978 | 2.3762 | 0.018927 | 0.99749 |
HME1 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.025621 | 0.0764 | 0.3468 | 0.0310 | 1.0824 | 0.018946 | 0.97645 |
SK-BR-3 | Topotecan | Topo I | Chemotherapy | 0.016549 | -0.2711 | 0.7941 | 0.1919 | 1.9350 | 0.01923 | 0.98214 |
SUM159PT | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.024971 | 0.0916 | 0.5859 | 0.0023 | 1.1458 | 0.019444 | 0.99527 |
Hs 578T | AZD7762 | CHK1/2 | Cell cycle | 0.015096 | -0.5983 | 0.8646 | 0.4133 | 1.8783 | 0.01967 | 0.95944 |
HCC1806 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.052338 | 0.2620 | 0.3895 | 0.0353 | 0.9021 | 0.019916 | 0.9778 |